Intercept's liver disease drug proves highly effective in study

April 12, 2014 5:08 AM

9 0

(Reuters) - A drug being developed by Intercept Pharmaceuticals Inc led to significant improvement in signs of a rare liver disease that primarily affects middle-aged women, likely reducing the risk of need for liver transplant and of death, according to results of a late-stage clinical trial presented on Saturday.

Nearly half the patients suffering from primary biliary cirrhosis who received the drug, obeticholic acid, achieved the primary goals of the study, compared with 10 percent for those who received a placebo, researchers said.

Read more

To category page

Loading...